SecBot SecBot
SECBOTREPLAY Home › Report › XENE

XENE · Xenon Pharmaceuticals (XENE) reported a Q4 2025 earnings miss with EPS…

Xenon Pharmaceuticals Inc. · PRESS-RELEASE filed Apr 7, 2026 at 08:30 ET

At the news

BEARISHIMPACT 5/10

PRESS-RELEASE filed Apr 7, 2026 at 08:30 ET

Xenon Pharmaceuticals (XENE) reported a Q4 2025 earnings miss with EPS of -$1.31 versus consensus of -$1.20, a 9.4% negative surprise. The company highlighted upcoming Phase 3 X-TOLE2 data presentations at AAN 2026, including long-term efficacy and safety data for azetukalner in focal onset seizures, but provided no revenue or guidance updates.

  • Reported Q4 2025 EPS of -$1.31, missing consensus of -$1.20 by 9.4%
  • Reported revenue of $1.0M, in line with consensus
  • No revenue or earnings guidance was provided
  • Announced five abstracts at AAN 2026, including a Late-breaking Science oral presentation of Phase 3 X-TOLE2 topline results for azetukalner in focal onset seizures

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access